Cargando…
Comparison of the effect of rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on inducing chronic Parkinson's disease in mouse models
Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin-induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mech...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809117/ https://www.ncbi.nlm.nih.gov/pubmed/35039876 http://dx.doi.org/10.3892/mmr.2022.12607 |
_version_ | 1784643952072196096 |
---|---|
author | Zhang, Jing Sun, Bohao Yang, Jifeng Chen, Zhuo Li, Zhengzheng Zhang, Nan Li, Hongzhi Shen, Luxi |
author_facet | Zhang, Jing Sun, Bohao Yang, Jifeng Chen, Zhuo Li, Zhengzheng Zhang, Nan Li, Hongzhi Shen, Luxi |
author_sort | Zhang, Jing |
collection | PubMed |
description | Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin-induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mechanisms underlying PD and develop effective treatments. The chronic PD mouse models were established via treatment with rotenone or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) for 6 weeks. The effects of rotenone and MPTP in the mice were compared by assessing neurobehavior, neuropathology and mitochondrial function through the use of the pole, rotarod and open field tests, immunohistochemistry for tyrosine hydroxylase (TH), glial fibrillary acidic protein (GFAP), ionized calcium-binding adapter molecule 1 (Iba-1), neuronal nuclear antigen (NeuN) and (p)S129 α-synuclein, immunofluorescence for GFAP, Iba-1 and NeuN, western blotting for TH, oxygen consumption, complex I enzyme activity. The locomotor activity, motor coordination and exploratory behavior in both rotenone and MPTP groups were significantly lower compared with the control group. However, behavioral tests were no significant differences between the two groups. In the MPTP group, the loss of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta, the reduction of the tyrosine hydroxylase content in the SN and striatum and the astrocyte proliferation and microglial activation in the SN were more significant compared with the rotenone group. Notably, mitochondrial-dependent oxygen consumption and complex I enzyme activity in the SN were significantly reduced in the rotenone group compared with the MPTP group. In addition, Lewy bodies were present only in SN neurons in the rotenone group. Although no significant differences in neurobehavior were observed between the two mouse models, the MPTP model reproduced the pathological features of PD more precisely in terms of the loss of DA neurons, decreased dopamine levels and neuroinflammation in the SN. On the other hand, the rotenone model was more suitable for studying the role of mitochondrial dysfunction (deficient complex I activity) and Lewy body formation in the SN, which is a characteristic pathological feature of PD. The results indicated that MPTP and rotenone PD models have advantages and disadvantages, therefore one or both should be selected based on the purpose of the study. |
format | Online Article Text |
id | pubmed-8809117 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-88091172022-02-03 Comparison of the effect of rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on inducing chronic Parkinson's disease in mouse models Zhang, Jing Sun, Bohao Yang, Jifeng Chen, Zhuo Li, Zhengzheng Zhang, Nan Li, Hongzhi Shen, Luxi Mol Med Rep Articles Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin-induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mechanisms underlying PD and develop effective treatments. The chronic PD mouse models were established via treatment with rotenone or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) for 6 weeks. The effects of rotenone and MPTP in the mice were compared by assessing neurobehavior, neuropathology and mitochondrial function through the use of the pole, rotarod and open field tests, immunohistochemistry for tyrosine hydroxylase (TH), glial fibrillary acidic protein (GFAP), ionized calcium-binding adapter molecule 1 (Iba-1), neuronal nuclear antigen (NeuN) and (p)S129 α-synuclein, immunofluorescence for GFAP, Iba-1 and NeuN, western blotting for TH, oxygen consumption, complex I enzyme activity. The locomotor activity, motor coordination and exploratory behavior in both rotenone and MPTP groups were significantly lower compared with the control group. However, behavioral tests were no significant differences between the two groups. In the MPTP group, the loss of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta, the reduction of the tyrosine hydroxylase content in the SN and striatum and the astrocyte proliferation and microglial activation in the SN were more significant compared with the rotenone group. Notably, mitochondrial-dependent oxygen consumption and complex I enzyme activity in the SN were significantly reduced in the rotenone group compared with the MPTP group. In addition, Lewy bodies were present only in SN neurons in the rotenone group. Although no significant differences in neurobehavior were observed between the two mouse models, the MPTP model reproduced the pathological features of PD more precisely in terms of the loss of DA neurons, decreased dopamine levels and neuroinflammation in the SN. On the other hand, the rotenone model was more suitable for studying the role of mitochondrial dysfunction (deficient complex I activity) and Lewy body formation in the SN, which is a characteristic pathological feature of PD. The results indicated that MPTP and rotenone PD models have advantages and disadvantages, therefore one or both should be selected based on the purpose of the study. D.A. Spandidos 2022-03 2022-01-17 /pmc/articles/PMC8809117/ /pubmed/35039876 http://dx.doi.org/10.3892/mmr.2022.12607 Text en Copyright: © Zhang et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Zhang, Jing Sun, Bohao Yang, Jifeng Chen, Zhuo Li, Zhengzheng Zhang, Nan Li, Hongzhi Shen, Luxi Comparison of the effect of rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on inducing chronic Parkinson's disease in mouse models |
title | Comparison of the effect of rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on inducing chronic Parkinson's disease in mouse models |
title_full | Comparison of the effect of rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on inducing chronic Parkinson's disease in mouse models |
title_fullStr | Comparison of the effect of rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on inducing chronic Parkinson's disease in mouse models |
title_full_unstemmed | Comparison of the effect of rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on inducing chronic Parkinson's disease in mouse models |
title_short | Comparison of the effect of rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on inducing chronic Parkinson's disease in mouse models |
title_sort | comparison of the effect of rotenone and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on inducing chronic parkinson's disease in mouse models |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809117/ https://www.ncbi.nlm.nih.gov/pubmed/35039876 http://dx.doi.org/10.3892/mmr.2022.12607 |
work_keys_str_mv | AT zhangjing comparisonoftheeffectofrotenoneand1methyl4phenyl1236tetrahydropyridineoninducingchronicparkinsonsdiseaseinmousemodels AT sunbohao comparisonoftheeffectofrotenoneand1methyl4phenyl1236tetrahydropyridineoninducingchronicparkinsonsdiseaseinmousemodels AT yangjifeng comparisonoftheeffectofrotenoneand1methyl4phenyl1236tetrahydropyridineoninducingchronicparkinsonsdiseaseinmousemodels AT chenzhuo comparisonoftheeffectofrotenoneand1methyl4phenyl1236tetrahydropyridineoninducingchronicparkinsonsdiseaseinmousemodels AT lizhengzheng comparisonoftheeffectofrotenoneand1methyl4phenyl1236tetrahydropyridineoninducingchronicparkinsonsdiseaseinmousemodels AT zhangnan comparisonoftheeffectofrotenoneand1methyl4phenyl1236tetrahydropyridineoninducingchronicparkinsonsdiseaseinmousemodels AT lihongzhi comparisonoftheeffectofrotenoneand1methyl4phenyl1236tetrahydropyridineoninducingchronicparkinsonsdiseaseinmousemodels AT shenluxi comparisonoftheeffectofrotenoneand1methyl4phenyl1236tetrahydropyridineoninducingchronicparkinsonsdiseaseinmousemodels |